clinical networks and senates
DESCRIPTION
Clinical networks and Senates. Professor Sir John Burn MD FmedSci Interim Clinical Director NHS Clinical Networks Northern England Thursday, 8 th November 2012. AHSN. CCRN. NHS. LETB. CN. HWB. Senate. Clinical engagement is critical to getting more for less. Between 2008 and 2011 - PowerPoint PPT PresentationTRANSCRIPT
Clinical networksand Senates
Professor Sir John Burn MD FmedSciInterim Clinical Director
NHS Clinical Networks Northern EnglandThursday, 8th November 2012
CN
AHSN CCRN
Senate HWB
LETBNHS
Clinical engagement is critical to getting more for less
Chairs of the Clinical Innovation Teams and Network Leads meet monthly
Between 2008 and 2011over 1000 North East Clinicians helped develop our programme of activity
We can network
Examples: Bill Cunliffe –Planned CareLiz Kendrick- End of Life Care
Philosophy: Care is best delivered by networks of clinicians able to act together and transcend structural system boundaries, standardise care and drive innovation
Governance– Must embrace diversity from the large and highly
structured to the loose more local partnerships
Limits– Geographical– Organisational
www.theclinicalnetwork.org
Chief Executive
Nurse DirectorMedical Director
Domain 3Domain 1 Domain 4 Domain 5Domain 2
Lead Nurse Medical Lead
CCGs, Providers, Patients and Clinicians
National Level
Sub national commissioning sector
Sub sector level
National Clinical Directors
Strategic Clinical Networks
TheClinical
networks and
Senates
What we know
• The Way Forward• 4 x Strategic Clinical Networks• 8 staff• £10m core + £32m programmes• Senates• Cumbria, North of Tyne and Wear Local Area Team• Single operating model
Constructing “Clinical Networks Northern England”
‘Clinical Networks Northern England’ –
Direction
Development Delivery
managing the transition to ‘Clinical Networks – Northern England’
ProfessionalPragmaticPatient Centred
EngagementFinancial securityambition
Integrated teamShared facilitiesRegular interactions
THE CLINICAL NETWORK PROGRAMME
PLANNED CARE ACUTE CARE LTC’S
CRO
SS C
UTT
ING
CLI
NIC
AL P
ROG
RAM
MES
CRO
SS C
UTT
ING
CLI
NIC
AL P
ROG
RAM
MES
CRO
SS C
UTT
ING
CLI
NIC
AL P
ROG
RAM
MESVASCULAR
CANCER
MOTHERS AND CHILDREN
operational NETWORKS
STRATEGIC CLINICAL NETWORK
STRATEGIC CLINICAL NETWORK
STRATEGIC CLINICAL NETWORK
Regional Networks End Of Life, Learning Disability,respiratory
Critical care, burnsNeonates, pathology
CNS DISORDERSMental health, dementia, neurosciences
STRATEGIC CLINICAL NETWORK
Issues still to resolve
• Operational networks • Programme budgets• Degree of flexibility• Senates• HR arrangements• Single operating model
Senate/Network footprint & interactions
•CCGs•FTs•NHS Commissioning Board
•Specialised Commissioning Hubs•Local Authorities•Health & Wellbeing Boards•Local Education and Training Boards (LETBs)
•Universities•Academic Health Science Networks (AHSNs)•Health Innovation and Education Clusters (HIECs)•Comprehensive Clinical Research Networks (CCRNs)•(CLAHRCs)Collab.s for Leadership in Applied Health Research & Care
• Commissioning Support• Quality Observatories• Public Health Observatories
Senates
• Has same footprint as networks• Under shared management• We think
• It needs a trusted chair• It should assemble for specific cases• Form should follow function
Building the Models…
‘Fast Focus Session’
Before we get to the event, we need to be able to describe each model taking into account;
• Number of Consultants and specialist staff
• Number of Beds (staffed)• Rotas and Job Plans• Patients (and admission
patterns• Services• Hospitals• The Network• Centres• PAUs• Population• Distance to travel
To start the event, we need two models demonstrating how the network could operate. These models are based on facts and show the network in two configurations – 3 centre vs 4 centre
Captain Kirk signs his PADD
The tricorder
What is your first response?
• “I bet it won’t work”• ….”it can’t can it?!”• ….”but that would affect my budget…”• …”it’s from Newcastle!”• ….”it’ll cause ethical problems”• ….”I hope it doesn’t work”
2001
Cui, Y., Wei, Q.Q., Park, H.K. & Lieber, C.M. Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science 293, 1289–1292 (2001).
“Devices based on nanowires are emerging as a powerful platform for the direct detection of biological and chemical species, including low concentrations of proteins and viruses.” 1st July 2006 Analytic Chemistry
QMDx Sequencing principles
T
G
G
A
C
C
G
T
T
C
A
A
R
- ve - ve
- ve
- ve- ve- ve
- vePolymerase
C
Nanowire
QMDx Sequencing principles
C
T
G
G
A
C
C
G
T
T
C
A
A
- ve - ve
- ve
- ve- ve- ve
- ve
Electrical Field
R
100 Å
Debye Length
Nanowire
QMDx Sequencing principles
C
T
G
G
A
C
C
G
T
T
C
A
A
- ve - ve
- ve
- ve- ve- ve
- ve
Wash
R
Nanowire
elute 1
elute 2
elute 3
elute 4
elute 5
elute 6
elute 7
elute 8
elute 9
elute 10
0.00
1.00
2.00
3.00
4.00
5.00
6.00
Nanofilament DNA recovery from wax curl in 4 minutes
DNA
ng/μ
l
MicrofluidicThermal PCRIn 4 minutes
-250 250 750 1250 1750 2250 2750 3250 3750 42507000000000
7200000000
7400000000
7600000000
7800000000
Probe + Complimentary (50oC)
R
Time(s)
Res
ista
nce
(O
hm
s)
October 2012 £4m Nanomal grant with St George’s London to develop a point of care malaria test in 2
years
Langa Township August 2010
Warfarin project
Prof Ann Daly, Newcastle University
The cytochrome P450 CYP2C9 is responsible for the metabolism of S-warfarin.
Two known allelic variants CYP2C9*2 and CYP2C9*3 are associated with impaired hydroxylation of S-warfarin
> 5m people in Europe are prescribed the wrong warfarin dose
Aim: to develop a POC test to test for variantsfor use in clinics/GP surgery
•Integration is better than disintegration
•Standing still when all else changes equals moving backwards
•Have confidence in our professional skills
•Prove my business partners wrong-let’s put Q-Poc into practice in the north of England 1st